Seroprevalence of human T-cell lymphotropic virus type 1 and 2 in blood donors from the regional hospital of Valdivia, Chile

Chandía, Luis; Sotomayor, Cristina; Ordenes, Sylvia; Salas, Pilar; López, Mauricio; Otth, Carola

doi:10.1007/s00430-010-0166-x

Cited by 9 publications

(10 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in Europe and Japan, most HTLV‐infected donors are HTLV‐1 positive, whereas in the United States a higher prevalence of HTLV‐2 positivity is reported . Interestingly, a reduction of HTLV seroprevalence was reported in some regions of the Americas: it decreased from 0.0093% in 1990 to 0.0011% in 2010 in Canada, from 0.73% in 1991 to 0.24% in 2010 in Chile, and from 0.6% in 1995 to 2000 to 0.1% in 2002 to 2008 in the Minas Gerais Region (Brazil)…”

Section: Epidemiologymentioning

confidence: 99%

Human T‐lymphotropic virus and transfusion safety: does one size fit all?

Marano¹,

Vaglio

Pupella³

et al. 2015

Transfusion

View full text Add to dashboard Cite

Human T-cell leukemia viruses (HTLV-1 and HTLV-2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the safety of blood supplies. In Japan and Europe, most HTLV-infected donors are HTLV-1 positive, whereas in the United States a higher prevalence of HTLV-2 is reported. Many industrialized countries have also introduced universal leukoreduction of blood components, and pathogen inactivation technologies might be another effective preventive strategy, especially if and when generalized to all blood cellular products. Considering all measures available to minimize HTLV blood transmission, the question is what would be the most suitable and cost-effective strategy to ensure a high level of blood safety regarding these viruses, considering that there is no solution that can be deemed optimal for all countries.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Human T‐lymphotropic virus and transfusion safety: does one size fit all?

Marano¹,

Vaglio

Pupella³

et al. 2015

Transfusion

View full text Add to dashboard Cite

show abstract

“…Rates of 5–6% infection were found among blood donors of highly endemic areas, such as the Caribbean Islands and Japan [290–292]. In medium prevalence areas of South America, these rates are close to 2% [293–299]. Systematic screening for HTLV-1 in blood banks has become compulsory in many countries.…”

Section: Blv As a Model For Htlv Therapy And Preventionmentioning

confidence: 99%

Preventive and Therapeutic Strategies for Bovine Leukemia Virus: Lessons for HTLV

Rodríguez

Florins

Gillet

et al. 2011

Viruses

172

126

View full text Add to dashboard Cite

Bovine leukemia virus (BLV) is a retrovirus closely related to the human T-lymphotropic virus type 1 (HTLV-1). BLV is a major animal health problem worldwide causing important economic losses. A series of attempts were developed to reduce prevalence, chiefly by eradication of infected cattle, segregation of BLV-free animals and vaccination. Although having been instrumental in regions such as the EU, these strategies were unsuccessful elsewhere mainly due to economic costs, management restrictions and lack of an efficient vaccine. This review, which summarizes the different attempts previously developed to decrease seroprevalence of BLV, may be informative for management of HTLV-1 infection. We also propose a new approach based on competitive infection with virus deletants aiming at reducing proviral loads.

show abstract

“…Screening tests are usually enzyme-linked immunoassorbent assays (ELISAs) (3,5,18,43,66) or particle agglutination (PA) (33). Confirmatory tests are immunofluorescence (IF) (23) but mostly Western blot (WB) analyses (30,35,38,39,64,71).…”

mentioning

confidence: 99%